Identification of Various Recombinants in a Patient Coinfected With the Different SARS-CoV-2 Variants.
SARS‐CoV‐2
coinfection
recombination
spike gene
viral quasispecies
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
revised:
18
03
2024
received:
12
10
2023
accepted:
30
05
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
19
6
2024
Statut:
ppublish
Résumé
Viral recombination that occurs by exchanging genetic materials between two viral genomes coinfecting the same host cells is associated with the emergence of new viruses with different virulence. Herein, we detected a patient coinfected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta and Omicron variants and identified various recombinants in the SARS-CoV-2 full-length spike gene using long-read and Sanger sequencing. Samples from five patients in Japan with household transmission of coronavirus disease 2019 (COVID-19) were analyzed using molecular assays for detection and identification of SARS-CoV-2. Whole-genome sequencing was conducted using multiplex PCR with short-read sequencing. Among the five SARS-CoV-2-positive patients, the mutation-specific assay identified the Delta variant in three, the Omicron variant in one, and an undetermined in one. The undermined patient was identified as Delta using whole-genome sequencing, but samples showed a mixed population of Delta and Omicron variants. This patient was analyzed for viral quasispecies by long-read and Sanger sequencing using a full-length spike gene amplicon. In addition to the Delta and Omicron sequences, the viral quasispecies analysis identified nine different genetic recombinant sequences with various breakpoints between Delta and Omicron sequences. The nine detected recombinant sequences in the spike gene showed over 99% identity with viruses that were detected during the Delta and Omicron cocirculation period from the United States and Europe. This study demonstrates that patients coinfected with different SARS-CoV-2 variants can generate various viral recombinants and that various recombinant viruses may be produced during the cocirculation of different variants.
Sections du résumé
BACKGROUND
BACKGROUND
Viral recombination that occurs by exchanging genetic materials between two viral genomes coinfecting the same host cells is associated with the emergence of new viruses with different virulence. Herein, we detected a patient coinfected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta and Omicron variants and identified various recombinants in the SARS-CoV-2 full-length spike gene using long-read and Sanger sequencing.
METHODS
METHODS
Samples from five patients in Japan with household transmission of coronavirus disease 2019 (COVID-19) were analyzed using molecular assays for detection and identification of SARS-CoV-2. Whole-genome sequencing was conducted using multiplex PCR with short-read sequencing.
RESULTS
RESULTS
Among the five SARS-CoV-2-positive patients, the mutation-specific assay identified the Delta variant in three, the Omicron variant in one, and an undetermined in one. The undermined patient was identified as Delta using whole-genome sequencing, but samples showed a mixed population of Delta and Omicron variants. This patient was analyzed for viral quasispecies by long-read and Sanger sequencing using a full-length spike gene amplicon. In addition to the Delta and Omicron sequences, the viral quasispecies analysis identified nine different genetic recombinant sequences with various breakpoints between Delta and Omicron sequences. The nine detected recombinant sequences in the spike gene showed over 99% identity with viruses that were detected during the Delta and Omicron cocirculation period from the United States and Europe.
CONCLUSIONS
CONCLUSIONS
This study demonstrates that patients coinfected with different SARS-CoV-2 variants can generate various viral recombinants and that various recombinant viruses may be produced during the cocirculation of different variants.
Substances chimiques
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13340Subventions
Organisme : Miyagi Prefecture, Japan
Organisme : AMED
ID : JP20wm0125001
Organisme : JSPS KAKENHI
ID : 22K21137
Informations de copyright
© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Références
M. Pérez‐Losada, M. Arenas, J. C. Galán, F. Palero, and F. González‐Candelas, “Recombination in Viruses: Mechanisms, Methods of Study, and Evolutionary Consequences,” Infection, Genetics and Evolution 30 (2015): 296–307.
M. M. Lai, “RNA Recombination in Animal and Plant Viruses,” Microbiological Reviews 56, no. 1 (1992): 61–79.
S. Austermann‐Busch and P. Becher, “RNA Structural Elements Determine Frequency and Sites of Nonhomologous Recombination in an Animal Plus‐Strand RNA Virus,” Journal of Virology 86, no. 13 (2012): 7393–7402.
E. Simon‐Loriere and E. C. Holmes, “Why Do RNA Viruses Recombine?” Nature Reviews. Microbiology 9, no. 8 (2011): 617–626.
H. Wang, X. Cui, X. Cai, and T. An, “Recombination in Positive‐Strand RNA Viruses,” Frontiers in Microbiology 13 (2022): 870759.
F. Wu, S. Zhao, B. Yu, et al., “A New Coronavirus Associated With Human Respiratory Disease in China,” Nature 579, no. 7798 (2020): 265–269.
J. M. Wolf, L. M. Wolf, G. L. Bello, J. G. Maccari, and L. A. Nasi, “Molecular Evolution of SARS‐CoV‐2 From December 2019 to August 2022,” Journal of Medical Virology 95, no. 1 (2023): e28366.
O. Puhach, B. Meyer, and I. Eckerle, “SARS‐CoV‐2 Viral Load and Shedding Kinetics,” Nature Reviews. Microbiology 21, no. 3 (2023): 147–161.
B. J. Willett, J. Grove, O. A. MacLean, et al., “SARS‐CoV‐2 Omicron Is an Immune Escape Variant With an Altered Cell Entry Pathway,” Nature Microbiology 7, no. 8 (2022): 1161–1179.
V. P. Chavda, S. Vuppu, T. Mishra, et al., “Recent Review of COVID‐19 Management: Diagnosis, Treatment and Vaccination,” Pharmacological Reports 74, no. 6 (2022): 1120–1148.
W. L. Wu, C. Y. Chiang, S. C. Lai, et al., “Monoclonal Antibody Targeting the Conserved Region of the SARS‐CoV‐2 Spike Protein to Overcome Viral Variants,” JCI Insight 7, no. 8 (2022): e157597.
T. Sekizuka, K. Itokawa, M. Saito, et al., “Genome Recombination Between Delta and Alpha Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2),” Japanese Journal of Infectious Diseases 75, no. 4 (2022): 415–418.
R. D. S. Francisco Junior, L. G. P. de Almeida, A. P. Lamarca, et al., “Emergence of Within‐Host SARS‐CoV‐2 Recombinant Genome After Coinfection by Gamma and Delta Variants: A Case Report,” Frontiers in Public Health 10 (2022): 849978.
P. Combes, M. Bisseux, A. Bal, et al., “Evidence of Co‐Infections During Delta and Omicron SARS‐CoV‐2 Variants Co‐Circulation Through Prospective Screening and Sequencing,” Clinical Microbiology and Infection 28, no. 11 (2022): 1503‐e5.
A. Bolze, T. Basler, S. White, et al., “Evidence for SARS‐CoV‐2 Delta and Omicron Co‐Infections and Recombination,” Med 3, no. 12 (2022): 848–859.e4.
K. Shirato, N. Naganori, H. Katano, et al., “Development of Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019(nCoV‐2019) in Japan,” Japanese Journal of Infectious Diseases 73, no. 4 (2020): 304–307.
M. Nagashima, “Laboratory Diagnosis of SARS‐CoV‐2 Variants at Tokyo Metropolitan Institute of Public Health,” Ann Rep Tokyo Metr Inst Pub Health, (2022): 73 [in Japanese], https://www.tmiph.metro.tokyo.lg.jp/files/archive/issue/kenkyunenpo/nenpou73/bef3ab4500cdb1355d0a34e6bacf642a2.pdf.
K. Itokawa, “Alternative Primers for the ARTIC Network's nCov2019 Multiplex PCR”, https://github.com/ItokawaK/Alt_nCov2019_primers.
K. S. Lole, R. C. Bollinger, R. S. Paranjape, et al., “Full‐Length Human Immunodeficiency Virus Type 1 Genomes From Subtype C‐Infected Seroconverters in India, With Evidence of Intersubtype Recombination,” Journal of Virology 73, no. 1 (1999): 152–160.
A. Bal, B. Simon, G. Destras, et al., “Detection and Prevalence of SARS‐CoV‐2 Co‐Infections During the Omicron Variant Circulation in France,” Nature Communications 13, no. 1 (2022): 6316.
A. Moisan, B. Mastrovito, F. De Oliveira, et al., “Evidence of Transmission and Circulation of Deltacron XD Recombinant Severe Acute Respiratory Syndrome Coronavirus 2 in Northwest France,” Clinical Infectious Diseases 75, no. 10 (2022): 1841–1844.
R. J. Rockett, J. Draper, M. Gall, et al., “Co‐Infection With SARS‐CoV‐2 Omicron and Delta Variants Revealed by Genomic Surveillance,” Nature Communications 13, no. 1 (2022): 2745.
H. Gu, A. A. Quadeer, P. Krishnan, et al., “Within‐Host Genetic Diversity of SARS‐CoV‐2 Lineages in Unvaccinated and Vaccinated Individuals,” Nature Communications 14, no. 1 (2023): 1793.
C. Perales, Q. Chen, M. E. Soria, et al., “Baseline Hepatitis C Virus Resistance‐Associated Substitutions Present at Frequencies Lower Than 15% May Be Clinically Significant,” Infection and Drug Resistance 11 (2018): 2207–2210.
Y. Turakhia, B. Thornlow, A. Hinrichs, et al., “Pandemic‐Scale Phylogenomics Reveals the SARS‐CoV‐2 Recombination Landscape,” Nature 609, no. 7929 (2022): 994–997.
D. Focosi and F. Maggi, “Recombination in Coronaviruses, With a Focus on SARS‐CoV‐2,” Viruses 14, no. 6 (2022): 1239.
K. A. Lacek, B. L. Rambo‐Martin, D. Batra, et al., “SARS‐CoV‐2 Delta‐Omicron Recombinant Viruses, United States,” Emerging Infectious Diseases 28, no. 7 (2022): 1442–1445.
D. Yamasoba, K. Uriu, A. Plianchaisuk, et al., “Virological Characteristics of the SARS‐CoV‐2 Omicron XBB.1.16 Variant,” The Lancet Infectious Diseases 23, no. 6 (2023): 655–656.
A. M. Carabelli, T. P. Peacock, L. G. Thorne, et al., “SARS‐CoV‐2 Variant Biology: Immune Escape, Transmission and Fitness,” Nature Reviews. Microbiology 21, no. 3 (2023): 162–177.